Stock Performance - The stock price of Hutchison China MediTech (00013) has shown fluctuations over the past week, with a range of -0.51% and a volatility of 5.30% from February 7 to February 13, 2026 [2] - On February 13, the closing price was HKD 23.26, with a daily increase of 0.35% and a trading volume of approximately HKD 55.73 million; the net inflow of funds was HKD 5.205 million [2] - In the same period, the US stock (HCM.OQ) experienced a decline of 2.83%, closing at USD 14.75 on February 12 [2] - Technical indicators show that the MACD histogram remains negative, indicating short-term pressure, while the KDJ indicator suggests signs of oversold recovery [2] Business Developments - The company has achieved several milestones in business progress and global compliance [4] - A board meeting is scheduled for March 5, 2026, to review the annual performance for 2025 [4] - The Phase III study of the novel tyrosine kinase inhibitor, Solitomab, for treating warm antibody autoimmune hemolytic anemia has met its primary endpoint, with plans to submit a new drug application to the National Medical Products Administration of China in the first half of 2026 [4] - The antibody-drug conjugate candidates HMPL-A580 and HMPL-A830 are expected to initiate Phase I clinical trials in 2026 [4] - New drug applications for Vanucizumab and Savolitinib have been accepted and prioritized for review [4] - The Shanghai flagship production base has passed an FDA inspection with "zero 483 deficiencies," strengthening the global supply chain capabilities [4]
和黄医药全球合规里程碑与业务进展，股价震荡整理